Kelly Del Tredici, Michael Schön, Simone Feldengut, Estifanos Ghebremedhin, Sarah K Kaufman, Diana Wiesner, Francesco Roselli, Benjamin Mayer, Katrin Amunts, Heiko Braak
{"title":"早期 CA2 Tau 包涵体不能区分老年性 Tau 病和早期阿尔茨海默病","authors":"Kelly Del Tredici, Michael Schön, Simone Feldengut, Estifanos Ghebremedhin, Sarah K Kaufman, Diana Wiesner, Francesco Roselli, Benjamin Mayer, Katrin Amunts, Heiko Braak","doi":"10.3233/JAD-240483","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Neuropathologic studies of brains from autopsy series show tau inclusions (pretangles, neuropils threads, neurofibrillary tangles) are detectable more than a decade before amyloid-β (Aβ) deposition in Alzheimer's disease (AD) and develop in a characteristic manner that forms the basis for AD staging. An alternative position views pathological tau without Aβ deposition as a 'primary age-related tauopathy' (PART) rather than prodromal AD. Recently, an early focus of tau inclusions in the Ammon's horn second sector (CA2) with relative sparing of CA1 that occurs before tau inclusions develop in the entorhinal cortex (EC) was proposed as an additional feature of PART.</p><p><strong>Objective: </strong>To test the 'definite PART' hypothesis.</p><p><strong>Methods: </strong>We used AT8-immunohistochemistry in 100μm sections to examine the EC, transentorhinal cortex (TRE), and Ammon's horn in 325 brains with tau inclusions lacking Aβ deposits (average age at death 66.7 years for females, 66.4 years for males).</p><p><strong>Results: </strong>100% of cases displayed tau inclusions in the TRE. In 89% of cases, the CA1 tau rating was greater than or equal to that in CA2. In 25%, CA2 was devoid of tau inclusions. Only 4% displayed a higher tau score in CA2 than in the TRE, EC, and CA1. The perforant path also displayed early tau changes. APOE genotyping was available for 199/325 individuals. Of these, 44% had an ɛ4 allele that placed them at greater risk for developing later NFT stages and, therefore, clinical AD.</p><p><strong>Conclusions: </strong>Our new findings call into question the PART hypothesis and are consistent with the idea that our cases represent prodromal AD.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early CA2 Tau Inclusions Do Not Distinguish an Age-Related Tauopathy from Early Alzheimer's Disease.\",\"authors\":\"Kelly Del Tredici, Michael Schön, Simone Feldengut, Estifanos Ghebremedhin, Sarah K Kaufman, Diana Wiesner, Francesco Roselli, Benjamin Mayer, Katrin Amunts, Heiko Braak\",\"doi\":\"10.3233/JAD-240483\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Neuropathologic studies of brains from autopsy series show tau inclusions (pretangles, neuropils threads, neurofibrillary tangles) are detectable more than a decade before amyloid-β (Aβ) deposition in Alzheimer's disease (AD) and develop in a characteristic manner that forms the basis for AD staging. An alternative position views pathological tau without Aβ deposition as a 'primary age-related tauopathy' (PART) rather than prodromal AD. Recently, an early focus of tau inclusions in the Ammon's horn second sector (CA2) with relative sparing of CA1 that occurs before tau inclusions develop in the entorhinal cortex (EC) was proposed as an additional feature of PART.</p><p><strong>Objective: </strong>To test the 'definite PART' hypothesis.</p><p><strong>Methods: </strong>We used AT8-immunohistochemistry in 100μm sections to examine the EC, transentorhinal cortex (TRE), and Ammon's horn in 325 brains with tau inclusions lacking Aβ deposits (average age at death 66.7 years for females, 66.4 years for males).</p><p><strong>Results: </strong>100% of cases displayed tau inclusions in the TRE. In 89% of cases, the CA1 tau rating was greater than or equal to that in CA2. In 25%, CA2 was devoid of tau inclusions. Only 4% displayed a higher tau score in CA2 than in the TRE, EC, and CA1. The perforant path also displayed early tau changes. APOE genotyping was available for 199/325 individuals. Of these, 44% had an ɛ4 allele that placed them at greater risk for developing later NFT stages and, therefore, clinical AD.</p><p><strong>Conclusions: </strong>Our new findings call into question the PART hypothesis and are consistent with the idea that our cases represent prodromal AD.</p>\",\"PeriodicalId\":14929,\"journal\":{\"name\":\"Journal of Alzheimer's Disease\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Alzheimer's Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3233/JAD-240483\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/JAD-240483","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
背景:对尸检系列大脑进行的神经病理学研究表明,在阿尔茨海默病(AD)淀粉样蛋白-β(Aβ)沉积前十多年,就能检测到tau包涵体(前角蛋白、神经纤丝线、神经纤维缠结),并且其发展方式具有特征性,是AD分期的基础。另一种观点认为,没有 Aβ 沉积的病理性 tau 是 "原发性年龄相关 tauopathy"(PART),而不是前驱 AD。最近,有人提出,在内侧皮质(EC)出现tau包涵体之前,阿蒙角第二区(CA2)出现tau包涵体的早期病灶,而CA1则相对较少,这是PART的另一个特征:验证 "明确的 PART "假说:我们使用AT8-免疫组化技术对325例缺乏Aβ沉积的tau包涵体的大脑(女性平均死亡年龄为66.7岁,男性平均死亡年龄为66.4岁)的100μm切片的EC、跨脑皮质(TRE)和Ammon角进行了检查:结果:100%的病例在TRE中显示出tau包涵体。在 89% 的病例中,CA1 的 tau 含量大于或等于 CA2 的 tau 含量。在25%的病例中,CA2没有tau包涵体。只有 4% 的病例 CA2 的 tau 评分高于 TRE、EC 和 CA1。穿孔路径也显示出早期 tau 变化。有199/325人进行了APOE基因分型。在这些人中,44%的人具有ɛ4等位基因,这使他们患NFT晚期的风险更高,从而导致临床AD:我们的新发现对PART假说提出了质疑,并与我们的病例代表AD前驱期的观点一致。
Early CA2 Tau Inclusions Do Not Distinguish an Age-Related Tauopathy from Early Alzheimer's Disease.
Background: Neuropathologic studies of brains from autopsy series show tau inclusions (pretangles, neuropils threads, neurofibrillary tangles) are detectable more than a decade before amyloid-β (Aβ) deposition in Alzheimer's disease (AD) and develop in a characteristic manner that forms the basis for AD staging. An alternative position views pathological tau without Aβ deposition as a 'primary age-related tauopathy' (PART) rather than prodromal AD. Recently, an early focus of tau inclusions in the Ammon's horn second sector (CA2) with relative sparing of CA1 that occurs before tau inclusions develop in the entorhinal cortex (EC) was proposed as an additional feature of PART.
Objective: To test the 'definite PART' hypothesis.
Methods: We used AT8-immunohistochemistry in 100μm sections to examine the EC, transentorhinal cortex (TRE), and Ammon's horn in 325 brains with tau inclusions lacking Aβ deposits (average age at death 66.7 years for females, 66.4 years for males).
Results: 100% of cases displayed tau inclusions in the TRE. In 89% of cases, the CA1 tau rating was greater than or equal to that in CA2. In 25%, CA2 was devoid of tau inclusions. Only 4% displayed a higher tau score in CA2 than in the TRE, EC, and CA1. The perforant path also displayed early tau changes. APOE genotyping was available for 199/325 individuals. Of these, 44% had an ɛ4 allele that placed them at greater risk for developing later NFT stages and, therefore, clinical AD.
Conclusions: Our new findings call into question the PART hypothesis and are consistent with the idea that our cases represent prodromal AD.
期刊介绍:
The Journal of Alzheimer''s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer''s disease. The journal publishes research reports, reviews, short communications, hypotheses, ethics reviews, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer''s disease.